Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude Medical’s single-connector lead is approved

This article was originally published in The Gray Sheet

Executive Summary

FDA approves the first "four-pole" defibrillator connector system, allowing a single connection between a cardiac resynchronization therapy defibrillator (CRT-D) and its leads with one set screw, St. Jude announces Feb. 5. Traditional lead designs require three connections and four set screws. The new connector, known as IS-4 and also being developed by Medtronic and Boston Scientific, is meant to simplify surgical placement and provide a smaller product. St. Jude's "SJ4" system uses a Durata defibrillation lead and Promote CRT-D with SJ4 connectors. The firm will conduct a five-year post-approval study with up to 1,700 patients and gather additional data through its SCORE patient registry. Critics have called for greater pre-market human testing of such innovative lead designs for the sake of patient safety (1"The Gray Sheet" Dec. 15, 2008, p. 7)

You may also be interested in...

A Leading Question: When Is Human Testing Needed For ICD Approval?

Debate is surfacing in the medical and regulatory community over when clinical data is needed to approve new implantable cardioverter defibrillator technology

Horizon Sees Blockbuster Future For Tepezza After US Approval

Once a pariah because of its price-gouging, the new approval represents a change of tack from Horizon.

Medicinal Products Expert And Established Devices Leader Head Commission’s Medtech Unit

Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts